A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors. Issue 2 (December 2015) - Papadopoulos, Kyriakos; Tsai, Frank; Hamid, Omid; Xiao, Feng; Steele, Keith; Rebelatto, Marlon; Robbins, Paul; Karakunnel, Joyson; Lai, Dominic; Mahipal, Amit